Julie E. Bauman
The University of Arizona
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Julie E. Bauman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05121051 · Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy SmokersNational Cancer Institute (NCI) · recruiting · Cigarette Smoking-Related Carcinoma
- Ph2NCT03422536 · Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell CarcinomaUniversity of Arizona · completed · Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma · principal investigator
- Early Ph1NCT03402230 · Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy SmokersNational Cancer Institute (NCI) · completed · Cigarette Smoking-Related Carcinoma, Tobacco-Related Carcinoma
- Early Ph1NCT03182959 · Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell CancerUniversity of Arizona · completed · HNSCC, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT02775812 · Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI) · completed · Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Ph1/Ph2NCT02298595 · Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell CarcinomaJulie E. Bauman, MD, MPH · withdrawn · Carcinoma, Squamous, Squamous Cell Carcinoma, Oropharyngeal Neoplasms
- Ph1NCT02277184 · Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell CarcinomaJulie E. Bauman, MD, MPH · terminated · Carcinoma, Squamous Cell of Head and Neck
- Early Ph1NCT02023931 · Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral MucosaJulie E. Bauman, MD, MPH · completed · Healthy Subject
- Ph1NCT00996515 · A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor MalignanciesNew Mexico Cancer Research Alliance · completed · Advanced Solid Tumor Malignancies
- Ph2NCT00703976 · Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck CancerUniversity of Pittsburgh · completed · Cancer
- Ph1NCT00291707 · Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck CancerUniversity of Pittsburgh · completed · Head and Neck Cancer
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- University of Arizona Cancer Prevention Clinical Trials NetworkUG1CA242596 · NCI · UNIVERSITY OF ARIZONA · fiscal years 2019 to 2026 · $850,832 awarded in 2026Grant number is on one of their registry trials
- Clinical and Translational Oncology Program (CTOP)P30CA023074 · NCI · UNIVERSITY OF ARIZONA · fiscal years 2022 · $73,563 awarded in 2022Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Head and Neck Cancer SPOREP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Heath Devin Skinner, Jose P. Zevallos · fiscal years 2004 to 2026Named on NCT03182959, NCT02023931
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT02775812
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:31 UTC. The ranking covers the 200 most relevant of 40 PubMed records, and a shared surname and initials can bring in a namesake. All 40 on PubMed
- 409 citationsRCR 16.7
- Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.Clin Cancer Res · 2010316 citationsRCR 8.6
- Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.J Clin Oncol · 2013155 citationsRCR 4.4
- A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.Int J Radiat Oncol Biol Phys · 2015114 citationsRCR 4.5
- 102 citationsRCR 3.0
- T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.Cancer Discov · 202499 citationsRCR 10.0
- Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.Cancer Immunol Res · 201788 citationsRCR 2.7
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.Clin Cancer Res · 201586 citationsRCR 2.6
- Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.Cancer Prev Res (Phila) · 201685 citationsRCR 3.5
- Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.Clin Cancer Res · 201871 citationsRCR 2.2